Ligand Pharmaceuticals Incorporated (LGNZZ)

Ligand Pharmaceuticals Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Jan 13, 2026	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Market Capitalization	3,660	2,025	1,245	1,128	2,581	1,599
Market Cap Growth	64.00%	62.59%	10.35%	-56.28%	61.40%	-12.69%
Enterprise Value	3,446	1,812	1,061	1,121	2,589	1,264
Last Close Price	0.07	0.13	0.13	0.15	0.14	0.17
PE Ratio	75.34	-	23.88	-	45.18	-
PS Ratio	14.57	12.11	9.48	5.75	10.69	9.78
PB Ratio	3.85	2.44	1.78	1.89	3.14	2.25
P/TBV Ratio	5.95	4.42	4.18	8.11	7.85	-
P/FCF Ratio	118.99	21.26	27.04	8.99	36.86	31.90
P/OCF Ratio	114.68	20.86	25.12	8.19	32.76	29.30
EV/Sales Ratio	13.72	10.84	8.08	5.71	10.72	7.73
EV/EBITDA Ratio	60.23	31.11	22.90	27.11	22.09	18.31
EV/EBIT Ratio	158.03	78.73	108.04	369.11	39.07	30.77
EV/FCF Ratio	112.04	19.03	23.04	8.93	36.96	25.22
Debt / Equity Ratio	0.48	0.01	0.01	0.15	0.40	0.64
Debt / EBITDA Ratio	7.02	0.12	0.13	2.09	2.74	6.42
Debt / FCF Ratio	14.66	0.08	0.13	0.70	4.63	9.11
Net Debt / Equity Ratio	-0.22	-0.30	-0.23	-0.21	-0.02	0.06
Net Debt / EBITDA Ratio	-3.39	-4.27	-3.54	-3.00	-0.14	0.66
Net Debt / FCF Ratio	-6.94	-2.61	-3.56	-0.99	-0.24	0.90
Asset Turnover	0.21	0.19	0.17	0.19	0.18	0.11
Inventory Turnover	6.74	1.71	1.88	4.38	3.50	4.20
Quick Ratio	23.66	8.05	12.49	2.50	10.39	4.70
Current Ratio	24.69	8.93	14.15	2.67	11.15	5.00
Return on Equity (ROE)	5.42%	-0.53%	8.29%	-0.74%	9.98%	0.89%
Return on Assets (ROA)	1.48%	1.66%	0.79%	0.18%	3.11%	1.80%
Return on Invested Capital (ROIC)	3.36%	-6.59%	1.64%	-0.07%	8.50%	7.45%
Return on Capital Employed (ROCE)	2.00%	2.50%	1.30%	0.50%	5.30%	3.30%
Earnings Yield	1.33%	-0.20%	4.19%	-2.96%	2.21%	-0.19%
FCF Yield	0.84%	4.70%	3.70%	11.12%	2.71%	3.13%
Buyback Yield / Dilution	-6.20%	-3.00%	-5.27%	2.19%	-2.50%	14.84%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.